Literature DB >> 25563142

Screening for liver cancer during transplant waiting list: a multicenter study from South America.

Federico Piñero1, Sebastián Marciano, Margarita Anders, Federico Orozco, Alina Zerega, Carla Ramirez Cabrera, Matías Tisi Baña, Octavio Gil, Oscar Andriani, Eduardo de Santibañes, Lucas McCormack, Adrián Gadano, Marcelo Silva.   

Abstract

BACKGROUND AND AIMS: Surveillance during liver transplantation (LT) waiting list has scarcely been reported in South America. We aimed to describe hepatocellular carcinoma (HCC) surveillance during the LT waiting list in the daily practice. PATIENTS AND METHODS: A multicenter retrospective analysis in cirrhotic patients was carried out. All patients underwent an ultrasound (US) every 6 months and the last pre-LT US was compared with explanted liver findings. A false-negative case was considered when incidentally found HCC (iHCC) was detected, whereas a false-positive case was considered when HCC diagnosed before LT (cHCC) was not confirmed in the explanted liver. US performance was assessed after excluding cHCC patients referred to transplant evaluation.
RESULTS: Of 643 patients, 129 had HCC, of whom 92 had cHCC (71.3%) and 37 had iHCC (28.7%). Five patients (5.4%) had nonconfirmed cHCC (n=3 regenerative nodules, n=1 biliary hamartoma, and n=1 cholangiocarcinoma). Patients with iHCC had a higher MELD score (23±10 vs. 15±10; P<0.0001), and were more frequently Child-Pugh C (62.2 vs. 36.6%; P=0.006) compared with patients with cHCC. The number of US performed during waiting list was 1.7±1.6 (median 1.0). During transplant waiting list, the sensitivity and specificity of US were 33 and 99%, with positive and negative predictive values of 0.89 and 0.93, respectively. Multivariate analysis showed that the strongest variable related to iHCC finding was pre-LT Child-Pugh C status (OR 3.5; P=0.004).
CONCLUSION: Screening for liver cancer remains an important issue during transplant waiting list. However, the US screening method should be reviewed particularly for Child-Pugh C patients.

Entities:  

Mesh:

Year:  2015        PMID: 25563142     DOI: 10.1097/MEG.0000000000000272

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

Authors:  Federico Piñero; Fernando Rubinstein; Sebastián Marciano; Nora Fernández; Jorge Silva; Yanina Zambelo; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Carlos Miguez; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

2.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Authors:  Kristina Tzartzeva; Joseph Obi; Nicole E Rich; Neehar D Parikh; Jorge A Marrero; Adam Yopp; Akbar K Waljee; Amit G Singal
Journal:  Gastroenterology       Date:  2018-02-06       Impact factor: 22.682

3.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

4.  Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges.

Authors:  Federico Piñero; Jaime Poniachik; Ezequiel Ridruejo; Marcelo Silva
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

5.  Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis.

Authors:  Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer
Journal:  Hepatol Commun       Date:  2022-08-09

6.  Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.

Authors:  Federico Piñero; Josefina Pages; Sebastián Marciano; Nora Fernández; Jorge Silva; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Manuel Cobos; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  World J Hepatol       Date:  2018-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.